Europe’s Latest Biotech Breakthrough: Fully Human Albumin Binding (FHAB®) Domain Fusion Proteins
In a recent development that’s sending ripples through the biotech industry, the European Patent Office (EPO) has granted EU Patent No. EP3583125 B1 to a leading biotech company for their innovative Fully Human Albumin Binding (FHAB®) domain fusion proteins. This patent protects the company’s proprietary technology, which is set to revolutionize the way we develop and deliver therapeutic proteins.
What Are FHAB® Domain Fusion Proteins?
FHAB® domain fusion proteins are a new class of therapeutic proteins engineered by fusing the FHAB® domain to other therapeutic proteins. The FHAB® domain is derived from human serum albumin, a naturally occurring protein in the human body. This domain allows the therapeutic protein to bind to albumin in the bloodstream, enhancing its circulation time and improving its efficacy.
The Science Behind FHAB® Domain Fusion Proteins
The human body has an intricate system for transporting proteins in the bloodstream. One of the most important proteins in this system is serum albumin, which accounts for about 60% of the total protein content in the blood. Albumin plays a crucial role in maintaining the colloidal osmotic pressure of the blood and acts as a carrier for various endogenous and exogenous substances. The FHAB® domain is the portion of the albumin protein that is responsible for this binding capacity.
By fusing the FHAB® domain to therapeutic proteins, researchers can harness the benefits of albumin’s binding properties, extending the circulatory half-life of the therapeutic and improving its bioavailability. This leads to better efficacy and fewer doses required for treatment, ultimately reducing the cost and complexity of therapy.
Impact on Patients: Personalized Medicine and Frequent Dosage
For patients, the development of FHAB® domain fusion proteins means more effective and personalized treatments. The longer circulation time of these proteins in the bloodstream ensures that they remain active for a longer period, providing a continuous therapeutic effect. This is particularly important for patients with chronic conditions who require frequent dosing.
Impact on the World: A New Era in Biotech
The granting of this patent marks a significant milestone in the biotech industry, opening up new possibilities for the development of more effective and affordable therapeutic proteins. It could lead to a paradigm shift in the way we approach protein therapeutics, with potential applications in various fields such as oncology, neurology, and rare diseases.
Conclusion: A Promising Future
The European Patent Office’s granting of EU Patent No. EP3583125 B1 for FHAB® domain fusion proteins is an exciting development in the world of biotech. This innovative technology offers numerous benefits, including extended circulation time, improved bioavailability, and the potential for more personalized and cost-effective treatments. As research in this area continues to advance, we can look forward to a future where FHAB® domain fusion proteins play a significant role in revolutionizing the way we treat various diseases and conditions.
- FHAB® domain fusion proteins are a new class of therapeutic proteins engineered by fusing the FHAB® domain to other therapeutic proteins.
- The FHAB® domain is derived from human serum albumin, a naturally occurring protein in the human body.
- FHAB® domain fusion proteins extend the circulatory half-life of therapeutic proteins, improving their efficacy and reducing the cost and complexity of therapy.
- This development could lead to a paradigm shift in the way we approach protein therapeutics, with potential applications in various fields such as oncology, neurology, and rare diseases.
